Background
==========

Multimodality therapy clearly offers survival benefit over surgery alone, especially in high-stage cancers. In recent decades, preoperative chemoradiotherapy followed by surgery has been the standard therapy for locally advanced rectal cancer and its application is increasing in other cancers, such as esophageal cancer and gastric cancer \[[@b1-medscimonit-21-3068]\]. However, the treatment also exerts some severe adverse effects and some patients are not sensitive to pRCT \[[@b2-medscimonit-21-3068]--[@b4-medscimonit-21-3068]\]. Thus, to identify patients who will benefit from the therapy strategy is very important. Therapy response is correlated not only with tumor types and tumor microenvironment, but also with patient genetics. Several biomarkers have been investigated to see if they are correlated with the response to pRCT, including the genetic polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and epidermal growth factor receptor (EGFR) genes.

MTHFR can catalyze the conversion of 5,10-MTHF to 5-methylenetetrahydrofolate. There are 2 common polymorphisms in MTHFR -- C677T (rs1801133) and A1298C (rs1801131) -- that are widely investigated. Both of them can be used as predictors of the response to fluoropyrimidine-based chemotherapy \[[@b5-medscimonit-21-3068]\]. EGFR is a member of the human epithelial receptor tyrosine kinase family and is also known as HER-1. Its kinase activity can regulate downstream gene expression, cellular proliferation, inhibition of apoptosis, and angiogenesis \[[@b6-medscimonit-21-3068]\]. Its expression has been reported to be related to radiation resistance. A polymorphism in the EGFR gene has been reported to lead the substitution of an arginine (Arg) residue by a lysine (Lys) in codon 497 (G497A) \[[@b7-medscimonit-21-3068]\]. Another polymorphism variant in EGFR is the CA repeats in intron 1 (rs11568315). EGFR transcription activity declines with an increasing number of CA repeats \[[@b8-medscimonit-21-3068]\]. The alleles are carried as short (S) or long (L), according to the number of CA repeats. Although a series of studies have been performed to examine the association of MTHFR and EGFR polymorphisms with the tumor response to pRCT, the results were inconsistent and inconclusive. In the present study, we conducted a meta-analysis to evaluate the association of MTHFR and EGFR polymorphisms with the tumor response to pRCT.

Material and Methods
====================

Publication search
------------------

We performed a systematic search for published articles in the database of PubMed, EMBASW, Web of Science, Chinese National Knowledge Infrastructure, and Wanfang on the association of MTHFR or EGFR polymorphisms and the response to preoperative chemoradiotherapy up to March 30, 2015. The following keywords and subject terms were used: "the methylenetetrahydrofolate reductase gene OR MTHFR", "Epidermal growth factor receptor OR EGFR", "polymorphism OR polymorphisms", and "Chemoradiation OR chemoradiotherapy OR chemo-radiotherapy OR radio-chemotherapy". The retrieved articles were screened by 2 authors independently, according to the inclusion and exclusion criteria and the review articles and reference lists of the primary studies were also screened.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria: (1) evaluation of the association between MTHFR C677T, MTHFR A1298C, EGFR G497A, and EGFR CA repeat polymorphisms and response to preoperative chemoradiotherapy; (2) response to chemoradiotherapy was evaluated by tumor regression grade (TRG); (3) genotype frequency data could be obtained to estimate the odds ratio (OR) and 95% confidence interval (CI). Articles were excluded based on the following criteria: (1) the data of TRG were not specific to polymorphism; (2) studies with insufficient or duplicate data; (3) meeting abstracts, letters, or review articles.

Data extraction
---------------

Based on the inclusion and exclusion criteria, 2 investigators extracted the following information from all eligible studies: name of first author, year of publication, country of origin, ethnicity, age, sex ratio, cancer type, disease stage, chemotherapy drugs, radiation dose, and genotype frequency in responders and non-responders of MTHFR C677T, MTHFR A1298C, EGFR G497A, and EGFR CA repeat polymorphisms.

Quality score assessment
------------------------

Two independent investigators assessed the methodological quality of every eligible article according to the Newcastle-Ottawa Scale (NOS) basing on 3 aspects: selection, comparability, and exposure, with scores ranging from 0 to 9 \[[@b9-medscimonit-21-3068]\]. NOS score ≥7 was considered as high quality.

Statistical analysis
--------------------

In the study, TRG grades were defined as grade 1: the absence of residual cancer; grade 2: the presence of rare residual cancer cells; grade 3: an increase in the number of residual cancer cells but with fibrosis predominating; grade 4: residual cancer outgrowing fibrosis; and grade 5: the absence of regressive changes \[[@b10-medscimonit-21-3068],[@b11-medscimonit-21-3068]\]. Patients were subdivided into responders and non-responders (TRG 1--2 *vs.* 3--5 or 1 *vs.* 2--5). The pooled odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs) were calculated to assess the strength of the association between MTHFR C677T, MTHFR A1298C, EGFR G497A, and EGFR CA repeat polymorphisms and the response to preoperative chemoradiotherapy. A *p*-value \<0.05 was used to indicate statistically significant association. Pooled ORs were performed under 5 genetic models: allelic model, homozygote model, heterozygote model, dominant model, and recessive model. If the response was evaluated by both TRG 1--2 *vs.* 3--5 and 1 *vs.* 2--5, only the TRG 1--2 *vs.* 3--5 data was included for the overall analysis and subgroup analysis stratified by cancer type. However, both were included when the subgroup analyses were performed according to the responder definition. The heterogeneity among the studies was assessed by the chi-square test based on Q statistic test and *I*^2^ statistic tests. When *P*\<0.1 or *I*^2^ \>50%, the heterogeneity was considered to be significant and then the pooled OR and 95%CIs were evaluated by the random-effects model (DerSimonian-Laird method); otherwise, the fixed-effects model (Mantel-Haenszel method) was used \[[@b12-medscimonit-21-3068]\]. Potential publication bias was checked by Begg's funnel plots and Egger's test \[[@b13-medscimonit-21-3068],[@b14-medscimonit-21-3068]\]. Sensitivity analysis was also conducted to evaluate the stability of the final results by deleting each study in turn. Subgroup analyses according cancer type and responder definition were also performed. Stata 12.0 software (StataCorp, College Station, TX, USA) was used to perform all analyses.

Results
=======

Study characteristics
---------------------

The literature selection process is shown in [Figure 1](#f1-medscimonit-21-3068){ref-type="fig"}. After initial identification, a total of 147 items were obtained. Of them, 54 were duplicated papers, 45 were review or meeting abstracts, and 29 were irrelevant papers. Then, 19 articles were left for further screening according to the inclusion and exclusion criteria by reading the full text. Subsequently, 8 articles were excluded; the treatment response to pRCT in 5 of them was not evaluated by tumor regression grade (TRG) and 3 articles did not report data related to the selected SNP. Finally, 11 eligible articles were included in the present meta-analysis \[[@b15-medscimonit-21-3068]--[@b25-medscimonit-21-3068]\]. Eight studies were performed in rectal cancer \[[@b15-medscimonit-21-3068],[@b18-medscimonit-21-3068]--[@b22-medscimonit-21-3068],[@b24-medscimonit-21-3068],[@b25-medscimonit-21-3068]\] and 3 studies were performed in esophageal cancer \[[@b16-medscimonit-21-3068],[@b17-medscimonit-21-3068],[@b23-medscimonit-21-3068]\]. The methodological quality of each eligible article was assessed by NOS scale and all studies received a high NOS score (≥7, data not shown). [Table 1](#t1-medscimonit-21-3068){ref-type="table"} shows the characteristics of each study. The articles were published from 2006 to 2015. In the present study we finally analyzed 8 included studies containing 839 cases for MTHFR C677T \[[@b15-medscimonit-21-3068]--[@b21-medscimonit-21-3068],[@b24-medscimonit-21-3068]\], 5 studies involving 634 cases for MTHFR A1298C \[[@b15-medscimonit-21-3068],[@b18-medscimonit-21-3068],[@b20-medscimonit-21-3068],[@b21-medscimonit-21-3068],[@b24-medscimonit-21-3068]\], 3 studies containing 340 cases for EGFR G497A \[[@b21-medscimonit-21-3068],[@b22-medscimonit-21-3068],[@b25-medscimonit-21-3068]\], and 4 studies containing 396 cases for EGFR CA repeat \[[@b18-medscimonit-21-3068],[@b21-medscimonit-21-3068],[@b23-medscimonit-21-3068],[@b24-medscimonit-21-3068]\].

Meta-analysis results
---------------------

We firstly analyzed the association of MTHFR C677T with the response to pRCT under 5 genetic models. Overall, the C677T polymorphism was correlated with the response to pRCT in recessive model (CC *vs.* CTTT, OR=1.426(1.074--1.894), *P*=0.014, [Table 2](#t2-medscimonit-21-3068){ref-type="table"}), but not in allele model, homozygote model, heterozygote model, or dominant model. In subgroup analysis according to cancer type, a significant association was also found in recessive model in rectal cancer (CC *vs.* CTTT, OR=1.483(1.102--1.996), *P*=0.009, [Table 2](#t2-medscimonit-21-3068){ref-type="table"}), but no significant association existed in other genetic models. When the subgroup analysis was performed according to responder definition, a significant association was only found in recessive model in TRG 1--2 *vs.* 3--5 group (CC *vs.* CTTT, OR=1.423(1.046--1.936), *P*=0.025, [Table 2](#t2-medscimonit-21-3068){ref-type="table"}, [Figure 2](#f2-medscimonit-21-3068){ref-type="fig"}). The results suggest that patients (especially those with rectal cancer) carrying CC genotype might benefit from pRCT compared with CT or TT carriers. The association between MTHFR A1298C, EGFR G497A, and EGFR CA repeat polymorphisms and the response to pRCT was also examined; however, no significant association was identified in overall or subgroup analyses, only a trend that EGFR short (S) CA repeat might harbor a unfavorable role in response to pRCT in overall analysis (S *vs.* L, OR=0.639(0.397--1.030), *P*=0.066, [Table 2](#t2-medscimonit-21-3068){ref-type="table"}, [Figure 4](#f4-medscimonit-21-3068){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was performed to examine the influence of each single study on the estimated effects in all genetic models. For MTHFR C677T polymorphism, we arrived at almost the same results in all genetic models. For MTHFR A1298C, when the report by Hu et al. was deleted, a significant association was identified between the polymorphism and the response to pRCT under heterozygote model (AC *vs.* CC). For EGFR CA repeat, a significant association was also found between the polymorphism and the response when the report by Hu et al. was deleted. To evaluate the publication bias among the selected studies, Begg's funnel plot was used for polymorphisms of MTHFR C677T, MTHFR A1298C, and EGFR CA repeat, and symmetrical funnel plots were obtained in all genetic models (and data not shown), indicating lack of publication bias. In addition, Egger's test was also performed and the results indicated that no publication bias existed among all the studies for all the polymorphisms under 5 genetic models ([Table 2](#t2-medscimonit-21-3068){ref-type="table"}).

Discussion
==========

In the present study, we performed a meta-analysis by pooling 20 studies to investigate the association of MTHFR and EGFR polymorphisms with the tumor response to pRCT in cancers. The results suggested that MTHFR C677T might be correlated with the tumor response, while the polymorphisms of A1298C in MTHFR and G497A and CA repeat in EGFR were not associated with the response.

Preoperative chemoradiotherapy, also known as neo-adjuvant chemoradiotherapy, followed by surgery has provide an alternative choice for cancer therapy and offered survival benefit for several cancers, especially locally advanced rectal cancer, in which the treatment strategy has became a standard therapy. In high-stage esophageal cancer and gastric cancer, a series of studies proved that the patients undergoing pRCT combined with surgery had higher overall survival rate and disease-free survival rates compared with surgery alone or surgery combined with adjuvant therapy \[[@b26-medscimonit-21-3068]--[@b28-medscimonit-21-3068]\]. Nevertheless, pRCT also causes severe adverse effects and many patients show poor response to pRCT. Tumor response to treatment was correlated with tumor type and tumor microenvironment, as well as patient genetics, so it is important to discover the biomarkers to identify patients who will benefit from pRCT and advance the development of individual therapy.

In the past decade many researchers have focused on the investigation of the biomarkers in predicting the tumor response to pRCT; however, the results are not consistent and valuable biomarkers are still lacking. Because many studies have determined the association of MTHFR polymorphisms with the tumor response to pRCT, we performed a systematic search in literature databases for related studies and conducted a meta-analysis to investigate the association between MTHFR polymorphisms and the response to pRCT, also including the EGFR polymorphisms. The results suggested that MTHFR C677T might be correlated with the tumor response to pRCT under the recessive model in overall analysis, rectal cancer, and TRG 1--2 *vs.* 3--5 group, while other polymorphism exert significant association under all genetic models in overall analysis or subgroup analyses. In addition, only a trend of association between EGFR CA repeat and the tumor response to pRCT was found. To the best of our knowledge, this is the first meta-analysis to address the association between MTHFR and EGFR polymorphisms and the response to pRCT, in which we tried to pool all the potential related studies regardless of cancer type. However, some limitations existed in the study. Firstly, the study number and the sample size were very small, especially for EGFR polymorphisms and esophageal cancer, which also led to the lack of stability of the results for MTHFR A1298C polymorphism. Another limitation was that all the original studies were performed in white populations except for 1 that was carried out in Asians. Thus, further well-designed studies with larger sample sizes focusing on more ethnicities should be conducted to confirm the results.

Conclusions
===========

In summary, we obtained a comprehensive result from the current meta-analysis that MTHFR C677T polymorphism was correlated with the response to pRCT in overall and in rectal cancer, while MTHFR A1298C and EGFR G497A and CA repeat polymorphisms showed no significant association with the tumor response to pRCT.
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###### 

Characteristics of the included studies.

  Reference                     Country                      Ethnicity   Case   Age                                                 M/F      Cancer type         Stage                                  Therapy strategy   Chemotherapy drugs                      Radiation dose (Gy)   TRG Evaluation    Genotype method     Sample   Polymor-phisms
  ----------------------------- ---------------------------- ----------- ------ --------------------------------------------------- -------- ------------------- -------------------------------------- ------------------ --------------------------------------- --------------------- ----------------- ------------------- -------- --------------------------------------------
  Terrazzino et al., 2006       Italy                        Caucasian   125    60 (31--79)                                         80/45    Rectal cancer       T2,3,4                                 RCT + surgery      5-FU                                    45.0                  1--2 *vs.* 3--5   PCR                 Blood    MTHFR C677T; A1298C
  Sarbia et al., 2006           Germany                      Caucasian   68     57 (37--70)                                         60/8     Esophageal cancer   T3/T4                                  RCT + surgery      5-FU folinic acid etoposide cisplatin   40.0                  1 *vs.* 2--5      PCR-RFLP            Tumor    MTHFR C677T
  Warnecke-Eberz et al., 2009   Germany                      Caucasian   52     59 (38--73)                                         NA       Esophageal cancer   T2--4                                  RCT + surgery      Cisplatin/5-FU                          36                    1--2 *vs.* 3--5   TaqMan              Tumor    MTHFR C677T
  Balboa et al., 2010           Spain                        Caucasian   65     64 (37--85)                                         50/15    Rectal cancer       II/III                                 RCT + surgery      5-FU/capecitabine                       50.5                  1--2 *vs.* 3--5   SNaPshot            Blood    MTHFR C677T; A1298C, EGFR CA repeat
  Garcia-Aguilar et al., 2011   Spain                        Mixed       132    Responder: 56 (32--80); Nonresponder: 57 (26--87)   77/55    Rectal cancer       II/III                                 RCT + surgery      5-FU                                    50.4                  1 *vs.* 2--5      Sanger sequencing   Tumor    MTHFR C677T
  Cecchin et al., 2011          Italy                        Caucasian   238    61 (20--79)                                         159/79   Rectal cancer       T2,3,4                                 RCT + surgery      5-FU                                    45.0--50.4            1--2 *vs.* 3--5   TaqMan              Blood    MTHFR C677T; A1298C
  Hu-Lieskovan et al., 2011     Belgium; Slovenia; Germany   Caucasian   130    61 (33--83)                                         74/56    Rectal cancer       II/III/IV                              RCT + surgery      Capecitabine/cetuximab/5-FU             45/50.4               1--2 *vs.* 3--5   PCR-RFLP            Tumor    MTHFR C677T; A1298C, EGFR G497A; CA repeat
  Hu-Lieskovan et al., 2011     Belgium; Slovenia; Germany   Caucasian   130    61 (33--83)                                         74/56    Rectal cancer       II/III/IV                              RCT + surgery      Capecitabine/cetuximab/5-FU             45/50.4               1 *vs.* 2--5      PCR-RFLP            Tumor    MTHFR C677T; A1298C, EGFR G497A; CA repeat
  Paez et al., 2011             Spain                        Caucasian   128    65 (32--83)                                         97/31    Rectal cancer       II/III                                 RCT + surgery      5-FU/capecitabine                       45.0                  1--2 *vs.* 3--5   Dynamic array       Blood    EGFR G497A
  Lee et al., 2011              Taiwan                       Aisan       132    \<60, n=80; ≥60, n=68                               NA       Esophageal cancer   IIa or less, n=55; IIb or more, n=93   RCT + surgery      Cisplatin/5-FU                          40.0                  1--2 *vs.* 3--5   PCR                 Blood    EGFR CA repeat
  Lamas et al., 2012            Spain                        Caucasian   93     67 (39--86)                                         68/25    Rectal cancer       II/III                                 RCT + surgery      5-FU                                    50.4                  1--2 *vs.* 3--5   SNaPshot            Blood    MTHFR C677T; A1298C, EGFR CA repeat
  Sebio et al., 2015            Spain                        Caucasian   84     67.6 (42--80)                                       55/29    Rectal cancer       II/III                                 RCT + surgery      Capecitabine                            45.0                  1 *vs.* 2--5      Dynamic array       Blood    EGFR G497A

###### 

Summary of the meta-analysis results.

  Polymorphism          Genetic model   Cancer type             N                      OR (95%CI)             *P~OR~*     Effect model   I^2^ (%)   *P~Heter~*   *P~Begg~*   *P~Egger~*
  --------------------- --------------- ----------------------- ---------------------- ---------------------- ----------- -------------- ---------- ------------ ----------- ------------
  MTHFR C677T           C *vs.* T       All                     7                      1.178 (0.855--1.624)   0.317       R              53.6       0.044        0.230       0.562
                                        Rectal cancer           6                      1.223 (0.860--1.738)   0.263       R              58.7       0.033                    
  Esophageal cancer     1                                                                                                                                                    
  TRG 1--2 *vs.* 3--5   6               1.097 (0.779--1.544)    0.596                  R                      53.9        0.055                                              
  TRG 1 *vs.* 2--5      2               1.590 (0.967--2.614)    **0.068**              R                      45.9        0.074                                              
  CC *vs.* TT           All             7                       1.185 (0.603--2.328)   0.623                  R           51.2           0.056      0.548        0.835       
  Rectal cancer         6               1.274 (0.576--2.817)    0.550                  R                      57.8        0.037                                              
  Esophageal cancer     1                                                                                                                                                    
  TRG 1--2 *vs.* 3--5   6               1.063 (0.558--2.027)    0.852                  R                      48.2        0.086                                              
  TRG 1 *vs.* 2--5      2               2.221 (0.084--58.420)   0.632                  R                      76.0        0.041                                              
  CT *vs.* TT           All             6                       0.727 (0.378--1.401)   0.341                  R           44.2           0.096      0.548        0.746       
  Rectal cancer         5               0.776 (0.369--1.633)    0.504                  R                      52.0        0.064                                              
  Esophageal cancer     1                                                                                                                                                    
  TRG 1--2 *vs.* 3--5   6               0.689 (0.443--1.074)    0.100                  F                      31.9        0.197                                              
  TRG 1 *vs.* 2--5      2               1.233 (0.015--98.183)   0.925                  R                      85.5        0.009                                              
  CC *vs.* CTTT         All             7                       1.426 (1.074--1.894)   **0.014**              F           18.6           0.283      0.386        0.363       
  Rectal cancer         6               1.483 (1.102--1.996)    **0.009**              F                      35.6        0.170                                              
  Esophageal cancer     2               0.953 (0.365--2.492)    0.922                  F                      0.0         0.770                                              
  TRG 1--2 *vs.* 3--5   6               1.423 (1.046--1.936)    **0.025**              F                      37.8        0.154                                              
  TRG 1 *vs.* 2--5      3               1.619 (0.899--2.915)    0.108                  F                      0.0         0.664                                              
  Rectal cancer         2               1.766 (0.947--3.291)    **0.074**              F                      0.0         0.750                                              
  CCCT *vs.* TT         All             7                       0.913 (0.501--1.664)   0.767                  R           46.8           0.080      0.764        0.742       
  Rectal cancer         6               0.968 (0.476--1.970)    0.929                  R                      54.4        0.052                                              
  Esophageal cancer     1                                                                                                                                                    
  TRG 1--2 *vs.* 3--5   6               0.863 (0.580--1.283)    0.466                  F                      39.1        0.145                                              
  TRG 1 *vs.* 2--5      2               1.773 (0.041--76.720)   0.766                  R                      82.2        0.018                                              
  MTHFR A1298C          A *vs.* C       Rectal cancer           5                      0.978 (0.771--1.241)   0.857       F              21.0       0.281        0.806       0.976
  AA *vs.* CC           Rectal cancer   5                       1.169 (0.683--2.002)   0.569                  F           37.7           0.170      0.462        0.550       
  AC *vs.* CC           Rectal cancer   5                       1.418 (0.824--2.439)   0.207                  F           34.2           0.194      0.221        0.504       
  AA *vs.* ACCC         Rectal cancer   5                       0.875 (0.639--1.199)   0.406                  F           0.0            0.458      0.806        0.912       
  AAAC *vs.* CC         Rectal cancer   5                       1.285 (0.768--2.148)   0.340                  F           36.4           0.179      0.462        0.492       
  EGFR G497A            G *vs.* A       All                     2                      0.812 (0.561--1.176)   0.271       F              25.1       0.248                    
  GG *vs.* AA           All             2                       1.244 (0.519--2.982)   0.624                  F           5.9            0.303                               
  GA *vs.* AA           All             2                       0.994 (0.398--2.486)   0.990                  F           0.0            0.610                               
  GG *vs.* GAAA         All             3                       0.930 (0.431--2.007)   0.853                  R           60.9           0.078      1.000        0.423       
  TRG 1--2 *vs.* 3--5   2               1.267 (0.762--2.106)    0.362                  F                      15.6        0.276                                              
  TRG 1 *vs.* 2--5      2               0.913 (0.472--1.765)    0.362                  R                      76.3        0.040                                              
  GGGA *vs.* AA         All             2                       1.139 (0.488--2.662)   0.763                  F           0.0            0.384                               
  EGFR CA repeat        S *vs.* L       All                     4                      0.639 (0.397--1.030)   **0.066**   F              38.3       0.182        1.000       0.938
  Rectal Cancer         3               0.708 (0.299--1.677)    0.433                  R                      54.8        0.109                                              
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